Laboratory of Computational Neuro-Oncology

doi:10.1158/0008-5472.CAN-83-14-CVR. — Diffuse midline glioma (DMG) is a fatal brain tumour and a leading cause of cancer-related death in children, adolescents, and young adults. Credits: doi:10.1158/0008-5472.CAN-83-14-CVR.

Biomedical data science for children and young adults with brain tumours.

Selected Publications

Everolimus for children with recurrent or progressive low-grade glioma: results from the phase II PNOC001 trial.

Journal of Clinical Oncology (2024)

See more

Clinical, genomic, and epigenomic analyses of H3K27M-mutant diffuse midline glioma long-term survivors reveal a distinct group of tumors with MAPK pathway alterations.

Acta Neuropathologica (2023)

See more

Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways.

Cancer Discovery (2023)

See more

Upfront biology-guided therapy in diffuse intrinsic pontine glioma: therapeutic, molecular, and biomarker outcomes from PNOC003.

Clinical Cancer Research (2022)

See more

ELP1-medulloblastoma syndrome.

WHO Classification of Central Nervous System Tumours (2021)

See more

Pan-cancer analysis of whole genomes.

Nature (2020)

See more

Germline Elongator mutations in Sonic Hedgehog medulloblastoma.

Nature (2020)

See more

Germline GPR161 mutations predispose to pediatric medulloblastoma.

Journal of Clinical Oncology (2019)

See more

Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort

The Lancet Oncology (2018)

See more

Contact

Head of Group: Sebastian Waszak

Email: [email protected]

Office: AAB 2 38

Administrative Assistant: Marina Menna

Email: [email protected]

Office: SV 2515